GLPG Galapagos NV

170.76
+25.01  (+17%)
Previous Close 145.75
Open 172.33
Price To Book 7.08
Market Cap 9,361,592,727
Shares 54,823,101
Volume 1,990,723
Short Ratio
Av. Daily Volume 130,027

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data lower than expectations released June 28, 2018.
GLPG2737 - PELICAN
Adult CF patients who are homozygous for the Class II F508del mutation
Phase 2 trial initiation announced July 5, 2017.
Filgotinib
Non-infectious uveitis
Phase 2 completion of enrolment announced June 11, 2019.
GLPG1972 - ROCCELLA
Osteoarthritis
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2a postive top-line data released November 20, 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 3 trial initiation announced December 17, 2018.
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 data due 2Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
NDA filing due 2019.
Filgotinib
Rheumatoid arthritis (RA)
Phase 2 trial to be completed 2019/20
MOR106 IGUANA
Atopic dermatitis
Phase 2 enrolment to be completed in 2019.
GLPG1205 - PINTA
Idiopathic pulmonary fibrosis (IPF)
Phase 2 initiation announced January 7, 2019.
GLPG1690 - NOVESA
Systemic sclerosis
Phase 2 initiation announced April 23, 2019.
MOR106 GECKO
Atopic dermatitis